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Abstract
Introduction: Excessive sympathoadrenal activation in critical illness contributes directly to organ damage, and
high concentrations of catecholamines damage the vascular endothelium. This study investigated associations
between potential drivers of sympathoadrenal activation, circulating catecholamines and biomarkers of endothelial
damage and outcome in ST segment elevation myocardial infarction (STEMI)-patients, hypothesizing that the
catecholamine surge would reflect shock degree and correlate with biomarkers of endothelial damage.
Methods: This was a prospective study of 678 consecutive STEMI-patients admitted to a single high-volume
invasive heart centre for primary percutaneous coronary intervention (pPCI) from September 2006 to July 2008.
Blood samples were drawn immediately before pPCI. Plasma adrenaline, noradrenaline, syndecan-1 and
thrombomodulin were measured retrospectively with complete data in 571 patients (84%). Median follow-up time
was 28 (IQR 23 to 34) months. Follow-up was 99.7% complete. Outcomes were all-cause and cardiovascular
mortality, re-myocardial infarction and admission due to heart failure.
Results: Circulating noradrenaline and adrenaline correlated weakly but independently with syndecan-1 (rho = 0.15
and rho = 0.13, both P <0.01) and thrombomodulin (rho = 0.11 and rho = 0.17, both P <0.01), biomarkers of
glycocalyx and endothelial cell damage, respectively. Considering biomarkers, patients with shock pre-pPCI had
higher adrenaline and syndecan-1 and patients admitted to ICU post-pPCI had higher syndecan-1 (all P <0.05), and
in the patients with shock (n = 51) catecholamines correlated strongly with thrombomodulin and syndecan-1 (rho
= 0.31 to 0.42, all P <0.05). During follow-up, 78 (14%) patients died (37 cardiovascular deaths) and 65 (11%) were
admitted with heart failure. By multivariate Cox proportional hazards analyses, one quartile higher plasma
adrenaline was weakly but independently associated with both 30-day and long term mortality and heart failure
(30-day all-cause mortality hazard ratio (95% CI) 1.39 (1.01 to 1.92), P = 0.046; 30-day heart failure 1.65 (1.17 to 2.34),
P = 0.005; and long-term cardiovascular mortality 1.49 (1.08 to 2.04), P = 0.014). Furthermore, one quartile higher
syndecan-1 was also weakly but independently associated with long-term all cause mortality (1.26 (1.02 to 1.57), P
= 0.034).
Conclusions: In STEMI patients treated with pPCI, catecholamines correlated weakly with biomarkers of endothelial
damage, with the strongest correlations and highest adrenaline and syndecan-1 levels in patients with shock.
Furthermore, adrenaline and syndecan-1 were weakly but independently associated with mortality and heart
failure. Acute myocardial infarction appears to cause significant endothelial cell and glycocalyx injury and a parallel
increase in circulating catecholamines.
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Introduction
Excessive sympathoadrenal activation is a hallmark of
acute critical illness and the accompanying increase in
circulating catecholamines induces widespread dose-
dependent effects on metabolism and the vascular system
[1-3]. This ‘fight-or-flight’ response may, however,
become maladaptive and contribute to organ damage
[2-4], and in high concentrations, catecholamines directly
damage the vascular endothelium resulting in local
edema, endothelial cell swelling, necrosis and progressive
de-endothelialization [5,6]. In two independent cohorts
of trauma patients, we recently reported that plasma
adrenaline correlated strongly with circulating biomar-
kers of endothelial activation and damage [7,8] and that
the plasma adrenaline level was independently associated
with circulating syndecan-1 [9], a recognized biomarker
of endothelial glycocalyx degradation [10]. Furthermore,
non-surviving trauma patients had increased levels of
adrenaline and syndecan-1 and both predicted 30-day
mortality [7,9].
Acute myocardial ischemia and infarction (MI) imme-
diately activates the sympathoadrenal system resulting in
excessive increases in circulating levels of adrenaline
and noradrenaline [11,12], the latter through direct
release from the infarcted myocardium [12]. Apparently,
catecholamines induce opposite directed effects on the
endothelium (progressive activation and damage) [4-6]
and circulating blood (initial hypercoagulability followed
by progressive hypocoagulability and hyperfibrinolysis)
[4,13-18], and we infer that this reflects an evolutionary
adapted response aimed at maintaining blood flow
through a damaged and procoagulant microvasculature
in the (shocked) critically ill patient [4]. In accordance
with this notion, patients with cardiac arrest present
with hyperfibrinolysis on-scene (extreme hypocoagul-
ability as a result of excessive endothelial release of pro-
fibrinolytic factors) [19] and increased circulating levels
of endothelial derived biomarkers (syndecan-1, throm-
bomodulin, sICAM-1, sVCAM-1, sE-selectin) in the
hours after cardiopulmonary resuscitation [20,21].
Although acute critical illness, with shock/hypotension,
ischemia and reperfusion, massive tissue injury and sys-
temic infection/inflammation, activates and potentially
damages the endothelium [8,9,20-27], the relative contri-
bution of the concurrent neurohumoral, including sym-
pathoadrenal, activation to the endothelial injury and
ensuing (multiple) organ failure [2-4] is not known.
MI patients have varying degrees of hypotension/
shock and increases in circulating catecholamines, in the
absence of massive tissue injury. Given this, the aim of
the present study was to investigate associations I)
between potential drivers of sympathoadrenal activation
and/or endothelial damage and II) between circulating
levels of catecholamines and biomarkers of endothelial
glycocalyx (syndecan-1 [10]) and cell (soluble thrombo-
modulin, sTM [28-30]) damage and organ failure/
outcome, in patients with ST elevation MI (STEMI). We
hypothesized that shock and high catecholamine levels
would be associated with evidence of enhanced damage
to the glycocalyx and endothelium and that high levels
of both catecholamines and endothelial derived biomar-
kers would be associated with a poor outcome.
Here, we report that circulating adrenaline and nora-
drenaline levels in STEMI patients treated with percuta-
neous primary coronary intervention (pPCI) correlated
weakly with syndecan-1 and sTM, biomarkers of glyco-
calyx and endothelial cell damage, respectively, with the
strongest correlations and highest levels of adrenaline
and syndecan-1 in patients with shock prior to pPCI.
Furthermore, adrenaline was independently associated
with short-and long-term mortality and heart failure
(HF), and syndecan-1 was independently associated with
long-term mortality. These findings indicate that acute
MI causes significant endothelial glycocalyx and cell
injury and a parallel increase in circulating catechola-
mines and they support the notion that a dose-dependent
association exists between disease severity, sympathoa-
drenal activation and endothelial damage.
Materials and methods
Study population
A total of 730 patients were treated with pPCI for
STEMI at Gentofte University Hospital from September
2006 to September 2008 [31]. Plasma was retrospectively
analyzed for adrenaline, noradrenaline, syndecan-1 and
sTM in 678, 677, 628 and 574 patients, respectively,
with complete measurements of all 4 biomarkers in 571
patients, that is, the present study cohort. If patients
had more than one pPCI-procedure within this period,
the first procedure was defined as the index-procedure.
Inclusion criteria and STEMI definition are as follows:
chest pain >30 minutes and <12 hours and cumulative
persistent ST-segment elevation ≥4 mm in at least two
contiguous precordial ECG-leads or ≥2 mm in at least
two contiguous limb ECG-leads. A significant increase
in troponin I (TnI, >0.5 μg/l) was required for inclusion
in the present study. The study was approved by the
local scientific ethical committee and The Danish Data
Protection Agency, and complied with the Second
Declaration of Helsinki. Written informed consent was
obtained from all patients.
Baseline-and procedural data
Prospectively collected data (baseline, disease severity)
are as follows: hypertension, hypercholesterolemia and
diabetes (patients taking blood-pressure-, cholesterol-or
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glucose-lowering drugs, respectively, on admission and
for the latter, with fasting plasma glucose concentration
≥7 mmol/L or non-fasting plasma glucose concentration
≥11.1 mmol/L); previous diagnosis of MI; multivessel
disease (two-or three vessel-disease); complex lesions
(type C-lesions); stenosis degree (1 or >1 infarcted seg-
ments); number of lesions (1 to 5); presence of shock
prior to pPCI (systolic blood pressure ≤90 mmHg, need
for vasopressor therapy and/or cardiopulmonary resusci-
tation pre-hospital or at admission) and admission to
the ICU prior to hospital discharge.
TnI-levels were measured at admission and six hours
and twelve hours after admission; the peak TnI level was
used in the statistical analyses. C-reactive protein (CRP),
estimated glomerular filtration tate (eGFR) and standard
hematology analyses (hemoglobin, platelet, leukocyte and
neutrophil counts) were measured at admission.
The pPCI procedure was performed according to con-
temporary interventional guidelines using pre-treatment
with unfractionated heparin, acetyl salicylic acid and clo-
pidogrel. Subsequent medical treatment included anti-
ischemic, lipid-lowering and anti-thrombotic drugs
according to current treatment guidelines.
Follow-up and study end points
Follow-up was 99.7% complete (two patients were lost
to follow-up due to emigration). The study endpoints
were all-cause mortality, cardiovascular (CV) mortality,
re-MI and admission with clinical signs of HF (dyspnea,
fatigue, edema/stasis) combined with a discharge-diag-
nosis of HF. Follow-up data on mortality were collected
from the National Person Identification Registry which
holds information on vital status. Follow-up data on re-MI
and admission with HF were collected using hospital
source data as well as data from the Danish National
Board of Health’s National Patient Registry, using Interna-
tional Classifications of Diseases, tenth revision (ICD-10)
codes.Median follow-up time was 28months (IQR 23 to 34).
Blood sampling
Peripheral arterial blood was drawn from the femoral
sheath at the beginning of the procedure. Blood was
allocated to different containers including 4 ml ethylene-
diaminetetraacetic acid (EDTA) tubes and was centri-
fuged at 10,000 RPM for 10 minutes within 30 minutes
of collection. Plasma was stored in NuncCryo tubes
(Nunc, Roskilde, Denmark) at-80°C.
Enzyme linked immunosorbent assay (ELISA)
measurements
Biomarkers of sympathoadrenal activation (adrenaline,
noradrenaline) and endothelial glycocalyx (syndecan-1)
and endothelial cell damage (sTM) were measured by
commercially available immunoassays in EDTA plasma
according to the manufactures’ recommendations: for
adrenaline and noradrenaline (2-CAT ELISAFAST TRACK,
Labor Diagnostica Nord GmbH & Co. KG, Nordhorn,
Germany; lower limit of detection (LLD) 10 pg/ml
(adrenaline) and 50 pg/ml (noradrenaline), respectively;
for syndecan-1 (Diaclone SAS, Besancon, France; LLD
4.94 ng/ml); and for sTM (Nordic Biosite, Copenhagen,
Denmark; LLD 0.38 ng/ml). Values below LLD were
recorded as the LLD value (n = 62, 78, 8 and 4 for adre-
naline, noradrenaline, syndecan-1 and sTM, respectively).
Statistics
Statistical analysis was performed using SAS 9.1 (SAS
Institute Inc., Cary, NC, US). Data from patients strati-
fied according to adrenaline or syndecan-1 quartiles
were compared by Kruskal-Wallis and Chi-square/
Fisher´s exact tests, as appropriate, and by Bonferroni
corrected Wilcoxon Rank Sum and Chi-square/Fischer
exact post-hoc tests. Biomarker levels in patients strati-
fied according to shock prior to pPCI or ICU admission
before discharge were compared by Wilcoxon Rank
Sum tests. Correlations between biomarkers were inves-
tigated by Spearman´s correlations. The contribution of
baseline variables to the variation in syndecan-1 and
sTM levels was investigated by univariate and multivari-
ate linear regression analyses. The predictive value of
quartiles of adrenaline, noradrenaline, syndecan-1 and
sTM for 30-day and long-term all-cause mortality, CV
mortality, re-MI and HF were investigated by univariate
and multivariate Cox proportional hazards analyses. To
maintain robust models, only one variable per five
events was allowed in the multivariable Cox analyses of
each endpoint. Variables with the lowest P-value in uni-
variate Cox analysis were included until the maximum
allowed number of variables was reached. Data are pre-




Baseline characteristics and outcome in all patients and
in patients stratified according to adrenaline quartiles
are presented in Table 1. With increasing adrenaline
quartile, the noradrenaline level increased progressively
and more patients presented with shock prior to pPCI,
developed HF or died during follow-up. Patients in the
highest adrenaline quartiles tended to have lower eGFR
and more complex lesions (Type C).
When comparing biomarker levels in patients strati-
fied according to shock prior to pPCI or ICU admission
before discharge, adrenaline levels were higher in
patients with shock (Figure 1A) and syndecan-1 levels
were higher in patients with shock or ICU admission
before discharge (Figure 1B,E). sTM tended to be higher
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Table 1 Demography, baseline data and outcome in 571 consecutive STEMI patients treated with primary PCI
All patients Adrenaline Q1 Adrenaline Q2 Adrenaline Q3 Adrenaline Q4 P-value
Number = 571 Number = 143 Number = 143 Number = 142 Number = 143
Demography and cardiovascular risk factors
Age years 63 (55-72) 64 (54-74) 64 (55-73) 62 (56-70) 64 (57-71) NS
Male gender n (%) 419 (73%) 103 (72%) 97 (68%) 112 (79%) 107 (75%) 0.192
Hypertension n (%) 197 (35%) 51 (36%) 49 (34%) 51 (36%) 46 (32%) NS
Diabetes n (%) 55 (10%) 17 (12%) 13 (9%) 14 (10%) 11 (8%) NS
Current smoker n (%) 285 (50%) 70 (49%) 77 (54%) 70 (49%) 68 (48%) NS
Previous MI n (%) 33 (6%) 10 (7%) 8 (6%) 6 (6%) 4 (4%) NS
BMI kg/m2 26 (24-29) 26 (23-30) 26 (23-28) 26 (24-30) 26 (24-29) NS
Pre-and in-hospital symptoms
Symptom-to-balloon time min 200 (134-330) 195 (137-325) 225 (133-375) 205 (131-360) 180 (120-299) 0.172
Door-to-balloon time min 60 (31-110) 50 (30-101) 70 (32-120) 63 (36-110) 60 (31-103) NS
Clinical presentation
Shock prior to pPCI n (%) 51 (11%) 7 (6%) 9 (8%) 13 (12%) 22 (18%) 0.016a
Systolic BP mmHg 135 (115-150) 131 (115-150) 135 (116-150) 138 (119-150) 130 (110-150) NS
Diastolic BP mmHg 80 (70-90) 80 (70-90) 80 (70-90) 80 (70-90) 80 (70-90) NS
Left ventricular ejection fraction % 40 (30-50) 40 (30-50) 40 (30-50) 40 (30-50) 35 (25-45) NS
eGFR at admission ml/min 73 (60-88) 76 (64-89) 74 (56-88) 74 (62-88) 70 (54-85) 0.052
Hematology and biomarkers of myocardial necrosis and inflammation
Hemoglobin mmol/L 8.7 (8.1-9.3) 8.7 (8.1-9.2) 8.8 (8.2-9.3) 8.7 (8.1-9.3) 8.7 (8.2-9.2) NS
Platelet count x 109/L 282 (234-333) 280 (242-346) 292 (241-345) 284 (233-317) 271 (227-332) NS
Leukocyte count x 109/L 12.2 (9.8-15.1) 11.6 (9.3-14.5) 12.3 (10.1-15.3) 12.5 (10.4-14.9) 12.4 (9.9-15.5) NS
Neutrophil count x 109/L 9.2 (6.8-11.8) 8.8 (6.7-11.3) 8.9 (7.2-11.6) 9.5 (7.2-12.2) 9.3 (6.3-12.2) NS
Peak Troponin I µg/L 90 (28-244) 98 (24-242) 116 (33-261) 60 (21-213) 95 (38-255) NS
CRP mg/L 3 (1-9) 4 (1-11) 3 (2-9) 3 (1-7) 3 (2-10) NS
Sympathoadrenal activation and endothelial damage
Adrenaline pg/ml 59 (25-145) 13 (10-20) 37 (29-50) 83 (73-94) 283 (213-501) <0.0001abcdef
Noradrenaline pg/ml 191 (90-454) 117 (57-236) 150 (78-294) 214 (108-498) 441 (229-1,180) <0.0001abdef
Syndecan-1 ng/ml 92 (52-165) 84 (46-156) 81 (47-162) 95 (55-168) 101 (52-169) NS
Soluble thrombomodulin ng/ml 2.2 (1.6-3.1) 2.1 (1.6-3.1) 2.3 (1.7-3.2) 2 (1.5-2.8) 2.2 (1.7-3.2) 0.040
Infarction type
Lesion type A 83 (15%) 18 (13%) 23 (16%) 27 (19%) 15 (10%) 0.194
B 209 (37%) 52 (36%) 56 (39%) 54 (38%) 47 (33%)
C 278 (49%) 73 (51%) 63 (44%) 61 (43%) 81 (57%)
Infarct related artery LAD 262 (46%) 62 (43%) 66 (46%) 60 (42%) 74 (52%) 0.092
RCA 246 (43%) 62 (43%) 54 (38%) 69 (49%) 61 (43%)
Cx 58 (10%) 19 (13%) 20 (14%) 13 (9%) 6 (4%)
LM 3 1%) 0 (0%) 1 (1%) 0 (0%) 2 (1%)
Graft 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Complex lesion n (%) 278 (49%) 73 (51%) 63 (44%) 61 (43%) 81 (57%) 0.071
Multivessel disease n (%) 160 (28%) 47 (33%) 35 (24%) 37 (26%) 41 (29%) NS
Clinical outcome
ICU admission after pPCI n (%) 30 (6%) 8 (7%) 5 (4%) 8 (7%) 9 (7%) NS
Follow-up time months 28 (23-34) - - - -
All-cause mortality n (%) 78 (14%) 14 (10%) 23 (16%) 10 (7%) 31 (22%) 0.001af
CV mortality n (%) 37 (7%) 3 (2%) 10 (7%) 6 (4%) 18 (13%) 0.002a
Re-MI n (%) 46 (8%) 14 (10%) 10 (7%) 11 (8%) 11 (8%) NS
Admission due to heart failure n (%) 65 (11%) 9 (6%) 21 (15%) 12 (8%) 23 (16%) 0.023
Data from all patients and patients stratified according to adrenaline quartiles are displayed. Data are presented as medians (IQR) or number (%), with P-values
shown for variables with P <0.2, and in bold for P <0.05. Adrenaline quartiles (Q1 to Q4) were compared by Kruskal-Wallis and Chi-square/Fischer exact tests, as
appropriate, and by Bonferroni corrected Wilcoxon Rank Sum and Chi-square/Fisher exact post-hoc tests. Significant post-hoc test difference (P <0.05) between:
aQ1 and Q4, bQ1 and Q3, cQ1 and Q2, dQ2 and Q4, eQ2 and Q3, fQ3 and Q4.
BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; CV, cardiovascular; Cx, circumflex; eGFR, estimated glomerular filtration rate; LAD, left anterior
descending; LM, left main; MI, myocardial infarction; n, number; NS, non-significant; PCI, primary coronary intervention; RCA, right coronary artery; STEMI, ST
elevation myocardial infarction.
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in patients with shock or ICU admission (Figure 1C,F).
eGFR was lower in patients with shock (P <0.001) or
ICU admission (P <0.001) whereas noradrenaline, CRP
and peak-TnI levels were comparable in patients with
shock or ICU admission (data not shown).
Given that syndecan-1 was increased in both shocked
and ICU patients, patients stratified according to synde-
can-1 quartiles were investigated. With increasing synde-
can-1 quartile (33 ng/ml (IQR 19 to 40), 69 ng/ml (IQR 59
to 79), 123 ng/ml (IQR 104 to 144) and 248 ng/ml (IQR
206 to 299) in Q1 to Q4, respectively), more patients
had shock prior to PCI (Q1 to 4: 10%, 5%, 9% and 19%,
P = 0.011) and eGFR decreased (Q1 to 4: 74 ml/min,
76 ml/min, 72 ml/min and 71 ml/min, P = 0.023) whereas
neutrophils (Q1 to 4: 8.6 × 109/L, 9.4 × 109/L, 9.4 × 109/L
and 9.6 × 109/L, P = 0.038), platelet count (Q1 to 4: 271 ×
109/L, 283 × 109/L, 272 × 109/L and 296 × 109/L,
P = 0.036), CRP (Q1 to 4: 3 mg/ml, 3 mg/ml, 4 mg/ml and
4mg/ml, P = 0.002) and sTM (Q1 to 4: 1.8 ng/ml, 2.1 ng/ml,
2.3 ng/ml and 2.8 ng/ml, P <0.0001) increased. With
increasing syndecan-1 quartile more patients went to the
ICU post-PCI (Q1 to 4: 3%, 3%, 8% and 11%, P = 0.027)
and more patients died (30-day all-cause mortality Q1 to
4: 3%, 3%, 5% and 12%, P <0.002 and long-term all-cause
mortality Q1 to 4: 9%, 10%, 12% and 23%, P <0.004) or
were admitted with HF (30-day HFQ1 to 4: 2%, 5%, 6% and
10%, P = 0.008 and long-termHFQ1 to 4: 6%, 11%, 13% and
15%, P = 0.015) (data not shown).
Correlations between catecholamines, endothelial
damage and markers of shock and infarction degree
Adrenaline and noradrenaline were highly positively cor-
related (rho = 0.43, P <0.001) and both adrenaline and
noradrenaline correlated weakly positively with synde-
can-1 (rho = 0.13, P = 0.003 and rho = 0.15, P <0.001,






























































Figure 1 Plasma levels of adrenaline, syndecan-1 and thrombomodulin in STEMI-patients with or without shock prior to primary PCI
(n = 51 with shock, A-C) or ICU admission before discharge (n = 30 admitted to ICU, D-F). Medians with inter quartile ranges (IQR) are
shown for adrenaline (pg/ml, A and D), syndecan-1 (ng/ml, B and E) and thrombomodulin (ng/ml C and F). P-values for Wilcoxon Rank Sum
tests are shown. PCI, primary coronary intervention; STEMI, ST elevation myocardial infarction.
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P = 0.006, respectively) when investigated in all patients.
Since shock was associated with increased levels of adre-
naline and syndecan-1, correlations between catechola-
mines and biomarkers of endothelial damage were
investigated in patients stratified according to the pre-
sence or absence of shock prior to pPCI. In patients
with shock, adrenaline and noradrenaline correlated
even more strongly with syndecan-1 and sTM (Figure
2A-D) whereas they did not correlate in patients with-
out shock (data not shown).
In all patients, systolic blood pressure correlated nega-
tively with adrenaline (rho =-0.14, P <0.001) and noradre-
naline (rho =-0.10, P = 0.020) but positively with eGFR
(rho = 0.11, P = 0.012). eGFR correlated negatively with
adrenaline (rho =-0.11, P = 0.006), noradrenaline (rho
=-0.13, P = 0.002) and sTM (rho =-0.32, P <0.001). Peak
TnI correlated positively with both noradrenaline (rho =
0.09, P = 0.026) and sTM (rho = 0.13, P = 0.003).
Variables associated with biomarkers of endothelial
damage
By univariate linear regression, higher adrenaline and
noradrenaline, female gender, diabetes, shock prior to
pPCI and lower eGFR were associated with higher syn-
decan-1 levels but in the multivariate model only nora-
drenaline, diabetes and shock prior to pPCI were
independently associated with syndecan-1 (Table 2).
Variables associated univariately with higher sTM were
higher adrenaline, noradrenaline, age and peak TnI,
female gender, non-smoking status, diabetes, multivessel
disease and lower BMI and eGFR whereas only adrena-
line, diabetes, BMI and eGFR were independently asso-
ciated with sTM (Table 3). Although syndecan-1 and
sTM levels were strongly intercorrelated (rho = 0.28, P
<0.0001), they were not included in the multivariate



































































































Figure 2 Scatter plots showing correlations between plasma levels of adrenaline and noradrenaline and syndecan-1 and
thrombomodulin in STEMI-patients with shock prior to primary PCI (n = 51). A) adrenaline versus syndecan-1, B) noradrenaline versus
syndecan-1, C) adrenaline versus thrombomodulin and D) noradrenaline versus thrombomodulin. Rho and P-values are shown for Spearman
correlations. PCI, primary coronary intervention; STEMI, ST elevation myocardial infarction.
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Catecholamines, endothelial damage and outcome
During a median follow-up of 28 months (IQR 23 to 34),
78 (14%) patients died (37 (7%) from CV causes), 46 (8%)
had a re-MI and 65 (11%) were admitted with HF (Table
1). With regard to the time-point of deaths, 42% (n = 33)
of all-cause fatal events occurred after 30 days.
Log-rank tests based on Kaplan-Meier curves for
quartiles of adrenaline, syndecan-1 and sTM showed
significant associations between high levels of each bio-
marker and increased 30-day and long-term all-cause
and CV mortality (see Figure 3A-D for Kaplan-Meier
plots of 30-day all-cause mortality). Kaplan-Meier curves
for quartiles of adrenaline and noradrenaline also
showed an association with 30-day and long-term
admission for HF whereas syndecan-1 was only asso-
ciated with 30-day HF and sTM only with long-term HF
(data not shown).
When the associations between biomarkers and mor-
tality were investigated by univariate Cox analyses, each
increase in adrenaline, syndecan-1 or sTM quartiles was
associated with increased risk of 30-day (Table 4) and
long-term (all P <0.05, data not shown) all-cause and
CV mortality and HF. After adjusting for conventional
risk factors, adrenaline remained an independent predictor
of 30-day all-cause mortality and HF (Table 4) and of
long-term CV mortality (P = 0.014) and syndecan-1
remained an independent predictor of long-term all-cause
mortality (P = 0.034). Noradrenaline was a univariate pre-
dictor of long-term CV mortality (P = 0.031) and long-
term HF (P = 0.039). None of the investigated biomarkers
could predict re-MI (Table 4 and data not shown).
Compared to the independent predictive value of con-
ventional risk factors for outcome in MI patients in the
present study (age, systolic BP, eGFR, peak TnI, CRP,
Table 2 Variables associated with plasma syndecan-1 by univariate and multivariate (backwards selection) linear
regression analysis in 571 consecutive STEMI patients treated with primary PCI
Univariate Multivariate
R2 = 0.05
b (95%CI) t P b (95%CI) t P
Adrenaline 100 pg/ml 1.64 (0.58 to 2.71) 3 0.003 NS
Noradrenaline 100 pg/ml 1.20 (0.57 to 1.84) 4 <0.001 1.12 (0.46 to 1.78) 3 0.001
Male gender yes -24 (-41 to-8) -3 0.004 NS
Diabetes yes 29 (4 to 54) 2 0.024 31 (3 to 58) 2 0.032
eGFR ml/min -0.41 (-0.72 to-0.10) -3 0.009 NS
Peak TnI µg/L 0.04 (0 to 0.08) 2 0.051 NS
Shock prior to pPCI yes 43 (17 to 69) 3 0.002 35 (8 to 61) 3 0.010
Regression coefficients (b) with 95% confidence intervals (95%CI), t-and P-values and R2 displayed for the multivariate models. P-values are shown in bold for
variables with P <0.05. Predicted change in syndecan-1 (pg/ml) associated with one unit increase in adrenaline, noradrenaline, eGFR and peak TnI, being male or
having diabetes or shock prior to pPCI. eGFR, estimated glomerular filtration rate; pPCI, percutaneous primary coronary intervention; STEMI, ST elevation
myocardial infarction; TnI, troponin I.
Table 3 Variables associated with plasma thrombomodulin by univariate and multivariate (backwards selection) linear
regression analysis in 571 consecutive STEMI patients treated with primary PCI
Univariate Multivariate
R2 = 0.19
b (95%CI) t P b (95%CI) t P
Adrenaline 100 pg/ml 0.03 (0.02 to 0.05) 4 <0.0001 0.02 (0.01 to 0.03) 3 0.003
Noradrenaline 100 pg/ml 0.01 (0.00 to 0.02) 3 0.006 NS
Age years 0.02 (0.02 to 0.03) 6 <0.0001 NS
Male gender yes -0.37 (-0.60 to-0.15) -3 0.001 NS
BMI kg/m2 -0.03 (-0.06 to-0.01) -3 0.002 -0.04 (-0.06 to-0.02) -4 0.001
Current smoker yes -0.41 (-0.61 to-0.21) -4 <0.0001 NS
Diabetes yes 0.38 (0.04 to 0.72) 2 0.029 0.45 (0.13 to 0.76) 3 0.006
eGFR ml/min -0.02 (-0.02 to-0.02) -10 <0.0001 -0.02 (-0.02 to-0.01) -10 <0.0001
Peak TnI µg/L 0.00 (0.00 to 0.00) 3 0.008 NS
Multivessel disease yes 0.32 (0.10 to 0.55) 3 0.004 NS
Regression coefficients (b) with 95% confidence intervals (95%CI), t-and P-values and R2 displayed for the multivariate models. P-values are shown in bold for
variables with P <0.05. Predicted change in thrombomodulin (pg/ml) associated with one unit increase in adrenaline, noradrenaline, age, BMI, eGFR and peak TnI,
being male, smoker or having diabetes or multivessel disease. BMI, body mass index; eGFR, estimated glomerular filtration rate; PCI, primary coronary
intervention; STEMI, ST elevation myocardial infarction; TnI, troponin I.
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Figure 3 Kaplan-Meier plots showing 30-day all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients
stratified into quartiles of circulating adrenaline, noradrenaline, syndecan-1 and sTM levels. Survival times for the quartiles of each
biomarker are shown for: adrenaline (A), noradrenaline (B), syndecan-1 (C) and soluble thrombomodulin (sTM, D). Chi-square and P-values for
log-rank tests are shown.
Table 4 Cox Proportional Hazards models predicting 30-day all-cause and cardiovascular (CV) mortality and heart
failure in 571 consecutive STEMI patients treated with primary PCI.
Adrenaline Noradrenaline Syndecan-1 Thrombomodulin
HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P
All-cause mortality 30-day uni 1.42 (1.03-1.96) 0.032 NS 1.74 (1.23-2.45) 0.002 2.13 (1.46-3.11) <0.0001
multia 1.39 (1.01-1.92) 0.046 NS 1.29 (0.90-1.85) 0.166 NS
CV mortality 30-day uni 1.45 (1.02-2.05) 0.038 1.27 (0.91-1.78) 0.167 1.59 (1.11-2.28) 0.012 2.39 (1.54-3.68) <0.0001
multib 1.39 (0.98-1.96) 0.066 NS NS 1.49 (0.93-2.38) 0.098
Re-MI 30-day uni NS NS 0.71 (0.43-1.17) 0.176 NS
multic NS NS NS NS
Heart failure 30-day uni 1.40 (1.02-1.92) 0.041 1.31 (0.96-1.80) 0.091 1.66 (1.19-2.32) 0.003 1.53 (1.10-2.12) 0.011
multid 1.65 (1.17-2.34) 0.005 1.29 (0.93-1.79) 0.135 1.38 (0.98-1.94) 0.069 NS
Hazards ratios (HR) with 95% confidence intervals (HR (95% CI)) and P-values associated with increased quartiles of adrenaline, noradrenaline, syndecan-1 or
thrombomodulin are shown for univariate and multivariate analyses, with P-values in bold for variables with p <0.05. The applied multivariate Cox proportional
hazards models (MV) included variables significant for 30-day events in the univariate analyses: a(30-day all-cause mortality, n = 33) age (<0.001), systolic blood
pressure (<0.0001), eGFR (<0.0001), peak TnI (<0.001), multivessel disease (<0.01); b(30-day CV mortality, n = 28) systolic blood pressure (<0.001), eGFR (<0.0001),
peak TnI (<0.0001), multivessel disease (<0.01); c(30-day re-MI, n = 14) leukocyte count (<0.0001); d(30-day heart failure, n = 33) age (<0.0001), BMI (<0.01), CV,
cardiovascular; eGFR (<0.0001), CRP (<0.0001), peak TnI (<0.0001). BMI, body mass index; CRP, C-reaction protein; eGFR, estimated glomerular filtration rate; PCI,
primary coronary intervention; Re-MI, Re myocardial infarction; STEMI, ST elevation myocardial infarction, TN1, troponin I.
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multivessel disease, P-values displayed in Table 4 foo-
ter), the predictive value of the investigated biomarkers
was weak.
Discussion
Here, we report that circulating adrenaline and noradre-
naline levels in STEMI-patients treated with pPCI corre-
lated with syndecan-1 and sTM, biomarkers of glycocalyx
and endothelial cell damage, respectively, with the stron-
gest correlations, and highest adrenaline and syndecan-1
levels, in patients with shock. Furthermore, circulating
levels of adrenaline and syndecan-1 were associated inde-
pendently with short-and long-term mortality and HF
and with long-term mortality, respectively. These find-
ings demonstrate that acute MI appears to cause signifi-
cant endothelial cell and glycocalyx injury and a parallel
increase in circulating catecholamines. They also support
the notion that a dose-dependent association between
disease severity, sympathoadrenal activation and
endothelial damage exists in critically ill non-trauma
patients in accordance with that previously observed in
trauma patients [7,9].
The vascular endothelium comprises a single layer of
cells that lines every blood vessel in the body, covers a
total surface area of 4 to 7,000 m2, totaling a weight of
1 kilogram [32]. On top of the endothelium lies the gly-
cocalyx, an approximately 1 μm thick carbohydrate-rich
structure with antiadhesive and anticoagulant properties
that protects the endothelium and maintains vascular
barrier function [22,23]. The endothelium is critically
involved in the pathology of multiple diseases, in which
there exist a well established association between
endothelial dysfunction and/or damage and poor out-
come [8,9,20-24]. In the present study, we investigated
associations between potential drivers of sympathoadre-
nal activation, endothelial damage and outcome in
patients with increased sympathoadrenal activation in
the absence of massive tissue injury. Our findings con-
firmed, in a different cohort of patients, the previous
finding in trauma patients of associations between
shock, catecholamines, biomarkers of glycocalyx and
endothelial cell damage and outcome [7-9]. Although
the median circulating levels of adrenaline and noradre-
naline in trauma patients (290 pg/ml (IQR 190 to 720)
and 750 pg/ml (IQR 450 to 1,380), respectively) [7,9] are
four-to five-fold higher than the median levels observed
in STEMI-patients in this study (Table 1), STEMI-
patients in the highest adrenaline quartile, representing
the most critically ill and shocked patients, had catecho-
lamine levels comparable to those observed in trauma
patients [7,9]. Although we found correlations between
catecholamines and biomarkers of endothelial damage
in the whole patient cohort, these were weak and
strongest in patients with shock, in accordance with the
notion that a dose-response relationship may exist
between catecholamine levels and infliction of endothe-
lial injury [4-6].
Glycocalyx damage is associated with pathophysiologic
sequels, such as capillary leakage and edema formation,
accelerated inflammation, platelet activation and hyper-
coagulability and loss of vascular responsiveness [22]. It
is becoming increasingly evident that glycocalyx damage
represents the earliest stage of endothelial perturbation
[22,23]. In STEMI-patients, several factors may contri-
bute to glycocalyx damage, that is, ischemia-reperfusion
injury, shock, inflammation (TNF-a), hyperglycemia,
atrial natriuretic peptide and oxidized low density lipo-
protein (LDL). Thus, in accordance with previous stu-
dies reporting that shock [21,25-27] and hyperglycemia/
diabetes [7,23,33] are associated with glycocalyx damage,
shock and diabetes were independently associated with
circulating syndecan-1 in the present study (Table 2).
With increasing syndecan-1 quartile, the neutrophil and
platelet count and CRP increased whereas eGFR
decreased. The finding that patients with shock dis-
played the strongest correlations between catechola-
mines and endothelial damage supports the notion that
a threshold level exists above which catecholamines
exert deleterious effects on the endothelial glycocalyx
and cells.
We also found that syndecan-1 was associated inde-
pendently with mortality and, to the best of our knowl-
edge, this association has not been reported previously.
Given the emerging evidence for devastating effects of
glycocalyx damage in acute [9,22,27] and chronic [23]
illness, including cardiovascular disease [21-23], this
finding is notable.
In accordance with previous studies, higher age [34],
male gender [34,35], non-smoking [34,35], diabetes [34]
and impaired kidney function [36] were associated with
higher circulating sTM, in addition to higher adrenaline
levels, lower BMI, myocardial cell damage (TnI) and
multivessel disease. Circulating adrenaline, BMI, diabetes
and eGFR were independently associated with sTM
(Table 3), indicating that both life style factors and
acute critical illness may contribute to endothelial
damage.
In the present study, more patients in the highest
adrenaline quartile died or developed HF. Adrenaline
was independently associated with mortality and HF
which is in accordance with previous findings reporting
(varying degrees of) association between early increases
in circulating adrenaline levels and mortality in MI-
patients [11,37,38]. From a pathophysiologic point of
view, MI-induced sympathoadrenal activation may later
aggravate chronic atherosclerosis [39]. In some studies
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the early adrenaline surge in MI-patients has been cor-
related with the extent of myocardial damage/infarct
size [11,40] and left ventricular ejection fraction (LVFE)
[38]. Although we could not replicate these associations,
we found a borderline significant association between
adrenaline levels and complex lesions (Table 1). It
should be emphasized that the above findings do not
prove any cause-effect relationship between early adre-
naline levels, endothelial damage and poor outcome
post-MI since it is expected that the most critically ill
patients have the highest sympathoadrenal response and
the poorest outcome. Also, it is possible that differences
in the sympathoadrenal response attributed to gene
polymorphisms in adrenergic receptors may in part
explain our findings [41]. However, it is notable that the
most critically ill and shocked MI patients presented
with evidence of enhanced endothelial damage that cor-
related more strongly with catecholamines than in less
sick patients. Whatever drivers among shock, ischemia-
reperfusion injury, catecholamines, hyperglycemia, and
so on that inflict the greatest endothelial damage, the
magnitude of increase in endothelial derived biomarkers
may be interpreted as a surrogate for concurrent organ
damage and this may, in part, explain the negative pre-
dictive value associated with these biomarkers.
With regard to noradrenaline, this was a univariate pre-
dictor of long-term HF and CV mortality in this study.
Although noradrenaline is a strong predictor of poor out-
come in patients with asymptomatic left ventricular dys-
function [42] and chronic HF [3], the weak predictive
value for outcome compared with adrenaline may both
reflect that we investigated an early noradrenaline
response, which may peak after PCI [43], and that nora-
drenaline release is much more heterogeneous compared
to adrenaline release; for example, noradrenaline is
released directly from the infarcted myocardium [12].
The results presented here are subject to the limita-
tions inherent to observational studies and, therefore, do
not allow independent evaluation of the cause and effect
relationship between catecholamine levels, endothelial
damage and outcome, so evidence of potential cause
and effect relationships should come from adequately
designed prospective trial(s). We found a relatively low
prevalence of diabetes, previous MI and known HF
prior to STEMI. Thus, care should be taken if the
results are to be extrapolated to populations with very
different distributions of potential risk factors and logis-
tic facilities. Also, our geographical and organizational
conditions may not necessarily apply to other countries
and regions, and our findings should not be extrapolated
to settings without high volume PCI centers. Finally, we
did not have data on predictive ICU scores (Sequential
Organ Failure Assessment, Acute Physiology and
Chronic Health Evaluation, and so on) and we did not
have data on previous b-adrenergic receptor blockers
before admission.
Conclusions
The present study found an association between shock,
circulating catecholamine levels, biomarkers indicative
of endothelial damage, and outcome in STEMI-patients
treated with pPCI, in accordance with previous findings
in trauma patients. Patients in shock presented with the
highest levels of adrenaline and syndecan-1, and the cor-
relations between catecholamines and endothelial-
derived biomarkers were particularly strong in patients
in shock. These findings demonstrate that acute MI
appears to cause significant endothelial cell and glycoca-
lyx injury and a parallel increase in circulating catecho-
lamines. The predictive value of the endothelial-derived
biomarkers for outcome in STEMI patients may indicate
that these, in part, reflect the extent of acute (ischemic/
catecholamine induced) organ damage, thereby provid-
ing a prognostic value.
Key messages
• Sympathoadrenal activation is a hallmark of acute
critical illness but this fight-or-flight response may
become maladaptive and contribute to organ damage;
in high concentrations catecholamines directly damage
the vascular endothelium.
• In STEMI-patients circulating levels of adrenaline
and noradrenaline correlated with levels of thrombo-
modulin and syndecan-1, biomarkers of endothelial
cell and glycocalyx damage, with the strongest correla-
tions in patients in shock.
• STEMI-patients with shock prior to PCI had the
highest circulating adrenaline and syndecan-1 levels
and patients admitted to ICU after PCI had the highest
syndecan-1 levels.
• Circulating levels of adrenaline and syndecan-1
were associated independently with mortality and
heart failure.
• Acute MI appears to cause significant endothelial
cell and glycocalyx injury and a parallel increase in cir-
culating catecholamines; these findings support the
existence of a dose-dependent association between
disease severity, sympathoadrenal activation and
endothelial damage in critically ill non-trauma patients
in accordance with that previously observed in trauma
patients.
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